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Cytochrome P450 4F2 (CYP4F2) activity is thought to be a
factor in the pathogenesis of hypertension through its
bioactive metabolite 20-hydroxyeicosatetraenoic acid
(20-HETE). We previously found that a gain-in-function
CYP4F2 variant in a Chinese cohort was associated with
elevated urinary 20-HETE and hypertension. To further
explore this association we generated a transgenic mouse
model expressing CYP4F2 driven by a modified mouse
kidney androgen-regulated protein promoter. This
heterologous promoter regulated the expression of luciferase
and his-tagged CYP4F2 in transfected HEK 293 cells. In the
kidney of transgenic mice, CYP4F2 was localized to renal
proximal tubule epithelia and was expressed at a higher level
than in control mice, leading to increased urinary
20-HETE excretion. Assessment of CYP4F2 activity by an
arachidonic acid hydroxylation assay showed that 20-HETE
production was significantly higher in kidney microsomes of
transgenic mice compared to control mice, as was their
systolic blood pressure. There was a positive correlation of
blood pressure with urinary 20-HETE levels. Our results show
that increased expression of CYP4F2 in mice enhanced
20-HETE production and elevated blood pressure.
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The human cytochrome P450 4F2 (CYP4F2) gene (MIM
no. 604426) encodes an o-hydroxylase that catalyzes the
arachidonic acid (AA) to 20-hydroxyeicosatetraenoic acid
(20-HETE).1 Previous studies have demonstrated that
20-HETE participates in the development of hypertension by
regulating vascular and renal tubular functions.2–5 On one
hand, 20-HETE increases peripheral vascular resistance by
potently constricting small arteries or by sensitizing the vascular
smooth muscle cells to constrictor and myogenic stimuli. On
the other hand, 20-HETE causes natriuresis by inhibiting
sodium reabsorption. Recently, we found that a functional
haplotype of CYP4F2 with increased transcriptional activity was
associated with elevated urinary 20-HETE and hypertension in
a Chinese population.6 A similar result was reported that the
variant V433M in CYP4F2 was associated with the increase of
20-HETE excretion and systolic blood pressure (SBP) in a white
cohort.7 However, a different result showed that the variant
F434S in CYP4A11, another human 20-HETE synthase gene,
with reduced catalytic activity was associated with hypertension
in white populations.8 Therefore, CYP4F2 transgenic approach
would be a pivotal and irreplaceable strategy to clarify the
correlation between 20-HETE and blood pressure.
Heterologous promoters have been utilized to target
transgene expression to expected tissues at controllable level
in transgenic models. Native CYP4F2 is expressed at a high
level in the proximal tubules of the human kidney where it
accounts for the majority of renal 20-HETE production.1
Mouse kidney androgen-regulated protein (KAP) is one of
the most abundant proteins expressed in the proximal
tubules in response to different hormones such as androgen
and estrogen.9 Experimental evidence from many previous
transgenic models has shown that a 1542-bp fragment of the
KAP promoter could successfully regulate transgene expres-
sion in the kidney.10–14 Moreover, Soler’s recent study has
documented that a 224-bp truncated fragment of the KAP
promoter was sufficient to drive androgen-dependent
transactivation in the kidney.15 Herein, we chose the
truncated KAP promoter to highlight kidney-dominant and
inducible expression of CYP4F2 in transgenic mice.
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This study aims to develop a transgenic mouse model
expressing CYP4F2 under the control of the heterologous
KAP promoter, and to shed light on the impact of 20-HETE
on blood pressure through CYP4F2 gain-in-function.
RESULTS
KAP promoter activity in HEK293 cells
To identify the KAP promoter activity, we amplified the 224-
bp fragment from 50-flanking of the KAP gene to construct
pKAP-LUC and pKAP-CYP4F2/his expression vectors. The
expression of luciferase and his-tagged CYP4F2 was detected
after transient transfection into HEK293 cells. As illustrated
in Figure 1a, the luciferase activity of cells transfected with
the pKAP-LUC, after being normalized to Renilla luciferase
activity, was threefold over those with the pGL3-enhancer
control. Western blot analysis for CYP4F2 expression in cells
transfected with the pKAP-CYP4F2/his (Figure 1b) showed
2.6-fold of cross-reacting signal over the pGL3-enhancer
control using anti-CYP4F2 antibody, wherein endogenous
CYP4F2 was included. The recombinant CYP4F2 expression
was further verified by anti-his antibody. These results
confirmed the 224-bp KAP promoter activity in driving the
expression of the heterologous CYP4F2 gene in HEK293 cells.
Generation of CYP4F2 transgenic mice
The linearized pKAP-CYP4F2/his (Figure 2a) was micro-
injected into FVB/N mouse to generate transgenic mice. We
routinely screened the mice by PCR (data not shown) for the
integration of CYP4F2 using specific primers, and further
evaluated the presence of the transgene by Southern blot
analysis (Figure 2b). Three transgenic founders, F0-6
(female), F0-16 (female), and F0-56 (male), were successfully
bred to establish independent transgenic mouse lines. There
was no difference in the number of offsprings between male
and female, indicating the CYP4F2 gene may insert into
the autosomes of the three founders. Line F0-16 seemed to be
less reproducible and thereby the number of positive
transgenic pups per brood was fewer than the others.
CYP4F2 expression profile in transgenic mice by Western blot
analysis
CYP4F2 was expressed in all kidney samples of the three
transgenic lines, among which line F0-16 exhibited the
highest expression level (Figure 3a). Detailed expression
profile of female and male transgenic offspring in line F0-16
was illustrated in Figure 3b and c, respectively, demonstrating
a wide expression spectrum of CYP4F2. Densitometry
scanning (Figure 3d) revealed that the highest expression
level was in the kidney of male mice, about 2.5-fold over
female littermates. In addition, the extra-renal expression of
CYP4F2 was prominent in reproductive organs. These results
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Figure 1 | KAP promoter activity in transfected HEK293 cells.
(a) Relative luciferase activity assay. Using the Dual Luciferase
Reporter assay system, the relative luciferase activity is presented
as the ratio of luciferase activity of firefly to that of Renilla as
internal control. (b) Western blot analysis of CYP4F2 expression.
CYP4F2 level was determined by anti-CYP4F2 antibody and anti-
his antibody in cells transfected with the pKAP-CYP4F2/his (þ )
and the pGL3-enhancer (). The 53-kD band represented CYP4F2
expression, and the 36-kD GAPDH was shown as internal control.
Data are presented as mean±s.d. All experiments were
performed three times independently.
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Figure 2 | Schematic map of the linear pKAP-CYP4F2/his and
Southern blot analysis of CYP4F2 in transgenic mice. (a) The
fragment for microinjection contained the 224-bp KAP promoter,
CYP4F2 cDNA, 6 his tag, and SV40 enhancer. Arrow-indicated P1
and P2 are the primers specific for CYP4F2 to screen positive mice
by PCR. (b) Southern blot analysis. The hybridization bands of tail
DNA with specific CYP4F2 probe confirmed the integration of the
transgene in the three transgenic lines. WT: wild-type.
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indicate that human CYP4F2 was successfully expressed in
the kidney of transgenic mice, and the expression was
influenced by sexual hormones, especially by androgen.
CYP4F2 expression by immunohistochemistry
Immunohistochemistry was performed in the kidney, liver,
brain, and uterus from line F0-16 using anti-his antibody.
The immunostaining signal was abundant in the kidney and
uterus, moderate in the liver, and not in the brain (Figure 4),
which was consistent with the results of Western blot analysis.
In the kidney, positive staining was predominantly localized
in the proximal tubules, indicating a high level of CYP4F2
expression; and there was no immunostaining signal in the
glomerulus. The liver sections exhibited positive immunos-
taining in some hepatocytes of the liver lobule. An intense
staining could be observed throughout the uterus sections
apart from the endomembrane.
Increased x-hydroxylation activity of transgenic renal
microsomes
To address whether the overexpression of renal CYP4F2 was
in correspondence to increased 20-HETE synthesis, we
generated an AA hydroxylation reaction system in vitro.
Renal microsomes isolated from transgenic line F0-16 and
wild-type mice were incubated with AA. As illustrated in
Figure 5a, the 20-HETE production was significantly
higher in the transgenic group than in the wild-type group
(660 (408–1073) versus 298 (224–398) pmol/min/mg micro-
some, P¼ 0.003). Moreover, Western blot analysis for
CYP4F2 in the renal microsomes demonstrated that the
cross-reacting signal of transgenic mice was 3.5-fold over
wild-type controls (Figure 5b). From these results, we
conclude that the overexpressed CYP4F2 in the renal
microsomes contributed to increased 20-HETE production
in transgenic mice.
Increased urinary 20-HETE excretion in transgenic mice
The urinary 20-HETE level of transgenic mice was deter-
mined to evaluate the activity of CYP4F2 in vivo. 20-HETE
ELISA assay was performed for the measurement according
to Grates’s report.16 As shown in Table 1, both female and
male transgenic mice from all the independent lines had
increased urinary 20-HETE compared with wild-type con-
trols (Po0.05). The urinary 20-HETE of male mice from line
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Figure 3 | CYP4F2 expression by Western blot analysis. 53-kD CYP4F2 was detected using anti-his antibody, and 36-kD GAPDH is shown
as an internal control. (a) CYP4F2 expression in the kidney of three transgenic lines and wild-type (WT) control. (b) CYP4F2 expression profile
of female offspring in line F0-16. (c) CYP4F2 expression profile of male offspring in line F0-16. (d) Scanning densitometry of b and c. Data are
presented as mean±s.d. All experiments were performed three times independently.
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F0-16 was the highest of all. Male transgenic mice had higher
urinary 20-HETE than their female littermates (P¼ 0.046),
which was in accordance with higher renal CYP4F2
expression in male than in female mice. These results
demonstrate that the overexpressed CYP4F2 in transgenic
mice functioned and lead to an augment in urinary 20-HETE
excretion.
Elevated blood pressure in transgenic mice
To determine the effect of 20-HETE overproduction on blood
pressure, we measured the mouse blood pressure by external
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Figure 5 | The x-hydroxylation analysis of renal microsomes.
(a) Increased 20-HETE production by transgenic renal microsomes.
In the AA o-hydroxylation reactions, the 20-HETE production was
significantly higher in the transgenic (TG) group (660 (408–1073))
than in the wild-type (WT) group (298 (224–398)). (b) CYP4F2
expression in renal microsomes by Western blot analysis. The 53-kD
band of CYP4F2 was detected by anti-CYP4F2 antibody and anti-his
antibody, and the 36-kD GAPDH was shown as an internal control.
All experiments were performed three times independently.
Table 1 | Urinary 20-HETE of CYP4F2 transgenic mice
Group n 20-HETE (ng/ml) P-value
WT
Female 6 8.99 (3.17–25.47)
Male 7 12.45 (7.88–19.66)
Line F0-16
Female 6 40.23 (22.43–72.16) 0.0001
Male 6 73.28 (42.23–127.18) 0.000005
Line F0-56
Female 8 33.27 (20.67–53.53) 0.0003
Male 7 35.55 (23.95–52.77) 0.003
Line F0-6
Female 7 23.91 (14.24–40.13) 0.007
Male 10 41.36 (25.40–67.31) 0.0003
WT, wild-type.
As urinary 20-HETE was not normally distributed, it underwent logarithmic
transformation for analysis of variance and was shown as geometric mean (95% CI).
Figure 4 | CYP4F2 expression by immunohistochemistry. (b, d,
f and h) Kidney, liver, brain, and uterus of transgenic (TG) mice,
and (a, c, e and g) wild-type (WT) controls, respectively. Anti-his
antibody was used as primary antibody and positive stainings are
indicated by arrows, using Diaminobenzidin as the chromagen.
Micrographs were taken at  200 magnification. The bar
represents 100 mm. (1) glomerulus; (2) proximal tubule; (3) lobular
central vein; (4) hepatocyte of the lobule; (5) endometrium.
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tail pulse detection. As depicted in Table 2, the SBP of
transgenic mice was elevated with variable magnitude
compared with wild-type controls. The most conspicuous
increment of SBP was in line F0-16. Figure 6a better shows
the comparison. Male transgenic mice had significantly
higher level of SBP than female transgenic littermates
(P¼ 0.001). The changes in SBP basically paralleled the
changes in urinary 20-HETE shown in Table 1, and their
positive correlation was shown in Figure 6b with statistical
significance (R¼ 0.872, P¼ 0.005), indicating that the
20-HETE overproduction contributed to elevated blood
pressure in transgenic mice. To record the development of
hypertension in transgenic mice, we performed time course
measurement and found that the blood pressure was elevated
since early lives and was maintained at a high level throughout
late lives (Figure 7). In addition, the hypertensive phenotype of
transgenic mice was further verified by intra-arterial blood
pressure measurement (Supplementary Information).
Blood biochemical assays
Finally, we performed blood biochemical assays including
serum creatinine, blood urea nitrogen (BUN), and plasma
aldosterone determination to exclude some other factors
associated with the development of hypertension. As shown
in Table 3, all these parameters were at equal levels between
transgenic mice and wild-type controls. Therefore, the
development of hypertension in our model was not related
to kidney failure or hyperaldosteronism, which further
confirmed the causative role of 20-HETE in the development
of hypertension.
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Figure 6 | SBP of CYP4F2 transgenic mice. (a) Comparison of
SBP in CYP4F2 transgenic mice. The SBPs of transgenic mice from
the three transgenic lines were compared with the wild-type (WT)
controls. Data are presented as mean±s.d. *Po0.001 in the
analysis of variance. (b) Correlation of logarithmic urinary 20-HETE
with SBP. Pearson’s correlation coefficient and P-value are
indicated on the graph.
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Figure 7 | Time course blood pressure measurement. The
blood pressure of transgenic (TG) mice in line F0-16 (n¼ 12) and
wild-type (WT) controls (n¼ 9) aged 8 to 40 weeks was measured
at four-week intervals to record the development of hypertension.
The SBP of TG mice was elevated in early life and maintained at
higher levels than WT controls throughout late life.
Table 3 | Blood biochemical assays of CYP4F2 transgenic mice
Parameter WT (n=6) TG (n=5) P-value
Creatinine (mg per 100 ml) 0.31±0.16 0.39±0.13 0.372
BUN (mg per 100 ml) 28.54±3.94 27.78±0.99 0.664
Aldosterone (pg per 100 ml) 335.60±92.41 321.47±85.12 0.800
TG, transgenic; WT, wild-type.
Data are presented as mean±s.d.
Table 2 | SBP of CYP4F2 transgenic mice
Group n SBP (mm Hg) P-value
WT
Female 12 109.47±7.79
Male 10 117.06±8.11
Line F0-16
Female 8 123.30±4.33 0.00008
Male 7 135.49±3.02 0.000002
Line F0-56
Female 11 123.18±6.95 0.00002
Male 11 129.36±5.59 0.0002
Line F0-6
Female 6 112.83±7.08 NS
Male 9 122.56±10.93 NS
WT, wild-type; NS, not significant.
Data are presented as mean±s.d.
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DISCUSSION
This study offers a novel transgenic mouse model over-
expressing human CYP4F2 under the control of the
heterologous KAP promoter. CYP4F2 was proved to be
overexpressed, leading to an augment of 20-HETE produc-
tion, which, in consequence, contributed to elevated blood
pressure in CYP4F2 transgenic mice.
Native CYP4F2 is predominantly expressed in the kidney
and plays a pivotal role in the regulation of blood pressure
through the vasoactive and natriuretic effects of 20-HETE
metabolite.2–5 Based on the anatomical and functional
characters of CYP4F2 in the kidney, the heterologous KAP
promoter was used to control CYP4F2 expression in a
kidney-dominant pattern in transgenic mice. CYP4F2 was
successfully expressed in the kidney of transgenic mice, and
its renal localization was quite similar to the spatial
disposition of native CYP4F2 in the human kidney. To assess
the activity of the overexpressed CYP4F2, we performed the
hydroxylation assay in isolated renal microsomes. We found
20-HETE production was significantly higher in samples
isolated from transgenic mice than in those from control
mice, and the elevated 20-HETE production was in
respondence to the increased CYP4F2 expression level in
isolated renal microsomes from transgenic mice, indicating
the overexpressed CYP4F2 resulted in a high level of AA
o-hydroxylation into 20-HETE. The elevated urinary
20-HETE excretion could further substantiate this notion in
vivo. In addition, the CYP4F2 expressed in other extra-renal
tissues may also contribute to some extent to the increased
20-HETE level in the systemic circulation, which in return
exacerbated urinary 20-HETE excretion. The quantification
of 20-HETE in this study was performed using Grates’s
20-HETE ELISA method,16 by which the 20-HETE concentra-
tion was comparatively higher than that by GC-MS techni-
ques17 and was somewhat lower than that by fluorescent HPLC
analysis.18 However, the comparison between transgenic and
their wild-type littermates under the same background was
valid to reflect the effects of the overexpressed CYP4F2. The
aforementioned data suggest that the transgenic model with an
overexpression of CYP4F2 increased in 20-HETE production,
and could be used for clarifying the effect of CYP4F2 on blood
pressure through the 20-HETE pathway.
20-HETE has both prohypertensive and antihypertensive
properties.2–5 20-HETE promotes hypertension by vasocon-
striction in many microcirculatory districts that regulates the
vascular tone and homeostasis. On the contrary, 20-HETE
attenuates hypertension by the inhibition of ion reabsorption
that regulates the salt balance. In our study, two lines of
transgenic mice (F0-16 and F0-56) had significantly higher
SBP than the control. Transgenic line F0-16 with the highest
renal CYP4F2 expression and urinary 20-HETE had the
highest SBP level, which could likely account for the lowest
reproductivity in this line; whereas line F0-6 with relatively
low level of CYP4F2 and urinary 20-HETE failed to change
blood pressure. The average SBP positively correlated with
urinary 20-HETE level with statistical significance. Thus, our
results supported that a prohypertensive effect of 20-HETE
was in dominance. After excluding some other factors
associated with the development of hypertension, such as
kidney failure and hyperaldosteronism, we deduce 20-HETE
derived from the overexpressed CYP4F2 in the tubular system
of nephron may diffuse into the local and systemic
circulation where the vasoactive molecule elicited powerful
vasoconstriction action in the transgenic mice. In addition,
20-HETE synthesized in extra-renal organs may also increase
the peripheral vascular tone. The prohypertensive effect of
20-HETE was evident in the early lives of transgenic mice and
lasted throughout their late lives. As to the antihypertensive
action of 20-HETE by inhibiting salt reabsorption, we
presumed it was not overt enough to override the
prohypertensive effect. Previous investigations indicated that
20-HETE plays an important role in the renal adaptation to
elevated Naþ intake: Laffer et al.19 demonstrated that urinary
20-HETE excretion was 66% higher during salt loading than
during salt depletion in humans; another study also showed
that urinary 20-HETE excretion increased by 20% when rats
were fed a high salt diet.20 In this regard, we hypothesized
that our transgenic mice fed with normal salt diet did not
elicit strong ion reabsorption inhibition. The prohypertensive
effect of 20-HETE in our transgenic model through CYP4F2
gain-in-function was in agreement with our recent report
that a functional haplotype of CYP4F2 with increased
transcriptional activity was associated with elevated urinary
20-HETE and enhanced susceptibility of hypertension,6 and
was also in agreement with Ward et al.’s report7 that the
variant V433M in CYP4F2 was associated with the increase
of 20-HETE excretion and SBP. Many previous animal
models also supported that increased renal CYP activity and
20-HETE promoted hypertension: the delivery of CYP4A1
cDNA into Sprague–Dawley rat increased blood pressure, and
the transfer of antisense CYP4A1 cDNA into spontaneously
hypertensive rat attenuated the development of hyperten-
sion;21 other researches on spontaneously hypertensive rat
reported that the CYP4A2 gene was overexpressed in the
kidney,22 with increased renal 20-HETE, and the use of 20-
HETE synthesis inhibitor attenuated hypertension.23
In addition, the CYP4F2 expression in our transgenic mice
was found in a wide spectrum and was prominent in
reproductive organs other than in the kidney. The extra-renal
transgene expression was also found in other transgenic
models controlled by the 1542-bp KAP promoter: Ding’s
investigation of KAP-hATG transgenic mice revealed that
human angiotensinogin was restricted to the kidney and
epididymis of a male line10 and was induced by testosterone
treatment in female transgenic mice;11 human renin was
expressed in the kidney of all KAP-hREN transgenic lines and
was variable in other tissues;12 the reporter luciferase gene
displayed high expression levels in the kidney and reproduc-
tive organs of KAP-luciferase transgenic mice.13 The CYP4F2
expression was higher and wider in our model than in those
previous models. This may be explained by the truncation of
the 224-bp promoter, or by the potential role of the
Kidney International (2009) 75, 1288–1296 1293
X Liu et al.: CYP4F2 transgenic mice o r i g i n a l a r t i c l e
introduced SV40 enhancer in the pKAP-CYP4F2/his con-
struct as enhancer element was suggested to be required for
the KAP promoter activity.24 As to the prominent expression
of CYP4F2 in reproductive organs of the transgenic mice, it
may be explained that the truncated KAP promoter was
capable of driving sex hormone responsive expression as
native KAP is expressed in response to different hormones,
such as androgen and estrogen.25
Furthermore, we also found sex-dimorphous phenomena
in CYP4F2 expression, renal 20-HETE formation and SBP in
our transgenic model. The transgene expression in the kidney
was higher in male than in female mice; urinary 20-HETE
was higher in male transgenic mice than in female
littermates; and coincidently the average SBP was signifi-
cantly higher in male transgenic mice than in female
littermates. As to the nontransgenic mice, 20-HETE and
SBP had male mice dominance as well. The disparities
between gender in our study may be explained from two
aspects: one was that the 224-bp KAP promoter regulated
CYP4F2 expression in an androgen-responsive way; the other
was that androgen-mediated 20-HETE synthesis directly.
Several animal models have suggested a link between
20-HETE production and androgen: Holla et al.17 found
that androgen can induce the expression of mice cyp4a12,
20-HETE formation and hypertension; Sprague–Dawley rats
showed an increase in the renal 20-HETE and SBP level after
androgen induction.26 Our previous population study
including 132 participants had shown that the urinary
20-HETE level in men was slightly higher than in women
(P¼ 0.041).6 Another research involving 66 subjects docu-
mented that men had significantly higher levels of urinary
20-HETE than women (P¼ 0.007).27 In addition, a recent
study also reported men had significantly higher levels
of 20-HETE excretion when compared with women.7 Taken
together, our findings suggested that androgen partially
contributed to the overexpressed CYP4F2, increased
20-HETE production and elevated blood pressure.
In summary, we established for the first time a CYP4F2
transgenic mouse model. The overexpression of CYP4F2
successfully participated in the overproduction of 20-HETE,
and consequently resulted in elevated arterial blood pressure.
The novel CYP4F2 transgenic model provides a valid tool to
further elucidate the mechanism of CYP4F2–20-HETE path-
way on blood pressure.
METHODS
Plasmid constructions
The promoter fragment from 224 to þ 1 of the KAP gene was
obtained by PCR using mouse genomic DNA as template and
primers: 50-GCGGTACCGGGTGGTGCACCTAGTCAG-30 and
50-CCAGATCTCCAAAAAGAGTCCTCCTGG-30. The amplified pro-
duct was cloned into the KpnI /HindIII sites of the pGL3-enhancer
vector (Promega, Madison, WI, USA) to generate pKAP-LUC
plasmid. The CYP4F2 cDNA was amplified by PCR with primers
50-TGCCCTGCAGGATGTCCCAGCTGA-30 and 50-CTCTCTAGAT
CAATGATGATGATGATGATGGCTCAGGGGCTCCACCCGCAG-30
(an introduced 6 his tag was underlined) after reverse transcription
of human liver RNA. The amplified CYP4F2 cDNA was cloned into
the PstI / XbaI sites of the pKAP-LUC to generate pKAP-CYP4F2/his
construct. All constructs were confirmed with sequencing.
Transient transfection and luciferase assay
Kidney-derived human embryo kidney 293 (HEK293) cells were
cultured and co-transfected with the pKAP-LUC construct and the
pRL-TK plasmid (Promega), encoding Renilla luciferase as internal
control for luciferase assay, or transfected with the pKAP-CYP4F2/
his construct for Western blot analysis, using lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA, USA). Cells were harvested 24 h
after transfection. Luciferase assay was performed using Dual
Luciferase Reporter assay system (Promega) and a Lumat LB 9507
luminometer (Bethold Technologies, Bad Wildbad, Germany).
Generation of CYP4F2 transgenic mice
The pKAP-CYP4F2/his plasmid was digested by KpnI and BamHI to
a linear DNA fragment containing the 224-bp KAP promoter,
CYP4F2 cDNA and SV40 enhancer, and microinjected into FVB/N
mouse one-cell fertilized embryos to generate CYP4F2 transgenic
founders (Figure 3a). Mice were fed with standard mouse chow
and water ad libitum, and bred in a 12:12 h light–dark cycle system.
Transgenic mice of 14- to 20-week old were used for data collection
unless noted elsewhere, with age- and sex-matched wild-type
mice as controls. All experiments conformed with the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996).
Transgenic mice were identified by PCR and Southern blot. PCR
was performed using DNA isolated from tail biopsies with primers
50-TGGACCTACGCCTTCTATGA-30 and 50-CCACTTGTCACCAG
CACTCA-30 specific to human CYP4F2 cDNA. For Southern blot,
the CYP4F2 cDNA sequence was isolated from the pKAP-CYP4F2/
his by digestion with PstI and XbaI, labeled by [a-32P]dCTP (Furui
Biotechnology, Beijing, China) with random primer DNA labeling
kit (TaKaRa Biotech, Japan), and then hybridized with genomic
DNA digested with HindIII.
Western blot analysis
Total protein was extracted from transfected cells or tissues of
transgenic mice and the concentration was determined with the
Bradford method. Denatured protein was separated by electrophor-
esis and transferred onto poly (vinylidene fluoride) membranes at
41C. Membranes were subsequently incubated with anti-CYP4F2
antibody (1:1000) (Fitzgerald, Concord, MA, USA), anti-his anti-
body (1:1000) (Sigma-Aldrich, St Louis, MO, USA), or anti-
GAPDH antibody (1:10,000) (KangChen Bio-Tech, Shanghai,
China) as primary antibody, followed by alkaline phosphatase-
conjugated IgG (1:2000) as the secondary antibody. The final
detection reaction was performed with b-naphthyl acid phosphate
and Fast Blue B salt (Sigma-Aldrich).
Immunohistochemistry
Mice were killed and immediately perfused transcardiacally with ice-
cold PBS, followed by 4% paraformaldehyde in PBS. Organs were
isolated, fixed at 41C for additional 4 h, and then immersed in 30%
sucrose solution at 41C overnight. The samples were embedded in
low temperature paraffin wax, and 4-mm thick sections were then
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prepared and incubated with anti-his antibody (1:300) at room
temperature for 6 h. With Streptavitin Peroxidase-Conjugated (SP)
method, Diaminobenzidin (Maxmim Bio-Tech, Fuzhou, China) was
utilized as the chromagen to localize peroxidase activity. Photo-
micrographs were taken by an OLYMPS IX51 inverted microscope
with the OLYMPUSMicro software.
Preparation of renal microsomes and AA hydroxylation assay
Renal microsomes were prepared according to the method described
before1 for Western blot analysis and AA hydroxylation assay. The
conversion of AA to 20-HETE was assessed in a reaction mixture of
300ml volume containing 100 mM potassium phosphate buffer (pH
7.4), 3.3 mM MgCl2, 80mM AA (Cayman Chemical, Ann Arbor, MI,
USA), 1 mM NADPH (Roche Applied Science, Basel, Switzerland)
and 0.6mg/ml mouse renal microsomes. After violent vortex and
5 min preincubation at 371C, NADPH was added to start the
reaction at 371C for 30 min, then the 20-HETE production was
measured.
20-HETE ELISA assay
20-HETE ELISA kits (Detroit R&D, Detroit, MI, USA) were used in the
AA hydroxylation assay of renal microsomes and urinary 20-HETE
measurement following manufacturer’s instructions. Briefly, samples
were loaded to the 96-well plate that was coated with anti-20-HETE
antibody. The plate was read at 450 nm OD using an automatic ELISA
plate reader (Bio-Rad Model 680, Hercules, CA, USA), and the 20-
HETE concentrations were calculated from the standard curve.
Blood pressure measurement
The blood pressure of conscious mice was measured by tail-cuff
method using IITC Life Science Model 1631 tail pulse detection
system (IITC Life Science Model 1631, Woodland Hills, CA, USA)
according to the manufacturer’s instructions. Mice were trained for
5 days and acclimated mice were warmed at 331C in the heating
container for 5 min before measurement. One measurement session
involved 10 repetitions and at least three sessions were performed on
each mouse to calculate the average.
Blood biochemical assays
Blood samples were collected for biochemical assays including
serum creatinine, BUN, and plasma aldosterone determination.
Serum creatinine and BUN measurement was performed on the
Vitros 950 analyzer (Ortho-Clinical Diagnostics, Raritan, NJ, USA)
with the VITROS Chemistry Products CREA and BUN Slides
according to the manufacturer’s instructions. Plasma aldosterone
was determined by radioimmunoassay (Active Aldosterone Ria Kit,
DSL 8600, Diagnostic System Laboratories, Webster, TX, USA) using
Gama Immunoassay Counter (USTC Chuangxin Co., Ltd. Zonkia
Branch, Hefei, China).
Statistical analysis
Statistical analysis was run with SPSS version 10.0 for Windows
(SPSS, Chicago, IL, USA). 20-HETE concentration was not normally
distributed and was presented by geometric mean (95% CI). Mouse
SBP, serum creatinine, BUN, and plasma aldosterone were presented
by mean±s.d. Comparison between logarithmic urinary 20-HETE
and SBP was performed by one-way ANOVA, and their correlation
was identified by Pearson’s method. Serum creatinine, BUN, and
plasma aldosterone were compared by independent-sample t-test.
Statistical significance was defined at Po0.05.
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